Navigation Links
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
Date:6/8/2009

al," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Later this year we will complete Phase 1 testing of the IV dosage form of torezolid and plan to merge the oral and IV programs in Phase 3 testing early next year. Our aim is to make torezolid available to physicians and patients as soon as possible to address the growing unmet medical need for an effective and well tolerated new IV and oral treatment for drug-resistant infections."

About Torezolid (TR-701)

Torezolid is a second-generation IV/oral antibacterial drug in the oxazolidinone class. It is significantly differentiated from Zyvox(R) (linezolid), the only marketed drug in this class. Advantages of torezolid over linezolid include:

  • 4-8 fold greater potency than linezolid in vitro and in vivo
  • In vivo bactericidal activity
  • Activity against all clinically important, gram-positive, drug-resistant strains including those resistant to linezolid
  • Activity against clinically important atypical and gram-negative pathogens (Legionella, Chlamydia, Neisseria)
  • 16x lower rate of resistance development in MRSA
  • Once-daily and shorter course of therapy to promote better treatment compliance
  • Broader safety window enabling potential longer course of therapy
  • Possibility for expanded indications including bacteremia, severe CAP and osteomyelitis
  • Lower potential for drug-drug interactions including those with dietary tyramine, SSRIs and vasoconstrictors

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity agai
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
2. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
3. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
4. Trius Doses First Patient in Antibacterial Phase 2 Trial
5. PacificGMP Completes GMP Product Fill for Trius Therapeutics
6. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
7. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
11. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... NASHVILLE, Tenn. , Sept. 19, 2014  Over ... for the Future to Benefit the Radiation Oncology Institute ... was held at Golden Gate Park in San Francisco.  ... Dan Moore , CEO of Radiation Business Solutions, ... sponsorships, we have raised over $70,000 for the ROI ...
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... offering of passive safety devices to protect both clinicians ... Inc. (B. Braun) recently announced that the U.S. Food ... company,s Introcan Safety ® 3 Closed IV Catheter, ... IV Catheter. B. Braun made the announcement during ...
... goBalto , developer of new ... has raised an undisclosed amount in Series A financing ... and the West Health Investment Fund.  The funds ... to enhance Tracker™ , its Software-as-a-Service (SaaS) clinical ...
Cached Medicine Technology:Safety to the Power of Three: B. Braun Medical Inc. Announces Introcan Safety® 3 Closed IV Catheter 2goBalto Raises Series A Financing to Advance Cloud-based Health Technologies 2goBalto Raises Series A Financing to Advance Cloud-based Health Technologies 3
(Date:9/19/2014)... led by Medical College of Wisconsin (MCW) scientists has identified ... in rats, mice and in humans. The findings are published ... , Leah Solberg Woods, Ph.D., associate professor of pediatrics ... Wisconsin Research Institute, led the study and is the corresponding ... identified a gene called Tpcn2 in which a variant was ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows web ... Bluehost are the best suppliers of 2014. Clients ... (including VPS and cloud hosting) at affordable rates ... , HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business companies ... of the cost. As a top rated hosting ...
(Date:9/19/2014)... cancer do not receive any palliative care, reveals new ... ESMO 2014 Congress in Madrid, Spain, 26-30 September. The ... time as 15 new oncology centres in Europe, Canada, ... title of ,ESMO Designated Centre of Integrated Oncology and ... oncology consultant at the Institute of Oncology Bucharest, Romania, ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Immunoassays are ligand assays used for detection ... antibodies in a given sample. Driven by steady ... overall healthcare industry, the global immunoassay systems market ... incidence of debilitating conditions, such as diabetes, cardio-vascular ...
(Date:9/19/2014)... TN (PRWEB) September 19, 2014 ... has been named a finalist for the 2014 ... founder and president Tammy Hawes has been selected ... the Year. The Nashville Area Chamber of Commerce ... these awards to recognize the accomplishments of companies ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3
... for about 10% to 20 % of women menopausal period ... sweats, hot// flashes (sensation of heat which comes on all ... Therapy (HRT) is the conventional treatment of choice that is ... period. Hormone therapy offers great relief from hot flashes and ...
... Telemedicine, the amalgamation of medicine and modern communications technology, ... monitor patients at a distance means they// can leave ... doctor, which also saves money. ,Christian Weigand, ... Circuits in Erlangen, Germany, said telemedicine could help people ...
... olive oil, glycerine and egg yolk would prevent ... ,The journal of Catheterization and Cardiovascular Interventions ... by Michael Savage, M.D., director, Cardiac Catheterization Laboratory ... mixture is not swallowed, Dr. Savage explains. Rather, ...
... the aging brain produces progressively fewer new nerve ... scientists said the finding, made in rodents, refutes ... cells persist in the aging brain. ... various neurodegenerative disorders, including Alzheimer's disease, dementia and ...
... diabetes and heart disease, lifestyle changes are making a ... study suggests that by reducing the intake beverages saturated ... their risk of developing cardiac diseases in the future. ... hypertension and type-2 diabetes has largely dealt with adults," ...
... signal an oncoming cold, many people reach for what ... tea or capsule containing //echinacea. In the first study ... bacteria in the gastrointestinal tract, research at the University ... side effects with this common herbal remedy. ,Although ...
Cached Medicine News:Health News:Natural Remedies Ineffective to Ease Menopausal Symptoms:study 2Health News:Telemedicine Offers New Possibilities in Health Care 2Health News:Olive Oil Emulsions Prevent Cardiac Bypass Surgery 2Health News:Stem Cell Activity Deciphered in the Aging Brain 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 3Health News:Echinacea: Cold-Season Cure or Risk? 2
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base....
... an independent laboratory to meet ... Standard 209E. Ergonomic seat guarantees ... back injuries. Clean vinyl meets ... chairs feature dissipative vinyl, conductive ...
Medicine Products: